CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) — insider trading
Health Care · NASDAQ
CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) has 19 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 3 open-market sales among the most recent 19 (latest 2026-06-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Jenkins John Kenneth | Director | Open-market sale | 4,800 | $7.91 | $38.0K | Form 4 |
| 2026-06-10 | Altmeyer Anne | Director | Open-market sale | 2,412 | $7.91 | $19.1K | Form 4 |
| 2026-06-10 | Kung Winston | Director | Open-market sale | 2,026 | $7.91 | $16.0K | Form 4 |
| 2026-06-03 | Saxena Nishant C | Officer (Chief Business Officer) | Open-market purchase | 9,000 | $7.58 | $68.2K | Form 4 |
| 2026-06-02 | Saxena Nishant C | Officer (Chief Business Officer) | Open-market purchase | 4,500 | $7.33 | $33.0K | Form 4 |
| 2026-05-21 | Saxena Nishant C | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 192,300 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Saxena Nishant C | Officer (Chief Business Officer) | Grant / award / vesting | 58,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Pfeiffenberger Brent | Director | Grant / award / vesting (derivative) | 24,700 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Pfeiffenberger Brent | Director | Grant / award / vesting | 7,500 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Ben Yong | Director | Grant / award / vesting (derivative) | 12,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Ben Yong | Director | Grant / award / vesting | 3,800 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Altmeyer Anne | Director | Grant / award / vesting (derivative) | 12,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Altmeyer Anne | Director | Grant / award / vesting | 3,800 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Jenkins John Kenneth | Director | Grant / award / vesting (derivative) | 12,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Jenkins John Kenneth | Director | Grant / award / vesting | 3,800 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Jacques Rachelle Suzanne | Director | Grant / award / vesting (derivative) | 12,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Jacques Rachelle Suzanne | Director | Grant / award / vesting | 3,800 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Kung Winston | Director | Grant / award / vesting (derivative) | 12,300 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Kung Winston | Director | Grant / award / vesting | 3,800 | $0.00 | $0 | Form 4 |
Ask the chat about CRBP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP).
Last updated 2026-06-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.